Simone Birch
YOU?
Author Swipe
View article: Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
Intra‐tumoral and peripheral blood <span>TIGIT</span> and <span>PD</span>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma Open
In classical Hodgkin lymphoma (cHL), responsiveness to immune‐checkpoint blockade (ICB) is associated with specific tumor microenvironment (TME) and peripheral blood features. The role of ICB in nodular lymphocyte predominant Hodgkin lymph…
View article: Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse
Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse Open
Introduction: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) continue to have poor outcomes despite introduction of innovative immune based therapies. Defining immune changes that occur within tumours at rela…
View article: Data from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Data from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma Open
Purpose: To investigate the relationship between the intra-tumoral T-cell receptor (TCR) repertoire and the tumor microenvironment (TME) in de novo diffuse large B-cell lymphoma (DLBCL) and the impact of TCR on survival.Experimental Design…
View article: Data from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Data from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma Open
Purpose: To investigate the relationship between the intra-tumoral T-cell receptor (TCR) repertoire and the tumor microenvironment (TME) in de novo diffuse large B-cell lymphoma (DLBCL) and the impact of TCR on survival.Experimental Design…
View article: Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma Open
Individual results of TCR sequencing for all DLBCL and non-diseased nodal tissues.
View article: Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
Supplementary Table 1 from The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma Open
Individual results of TCR sequencing for all DLBCL and non-diseased nodal tissues.
View article: Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry
Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry Open
Background Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to 80 entities now described. Lymphoma is the 6 th most common cancer in Australia, affecting patients of all age…
View article: Genetic aberrations of<i>NLRC5</i>are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
Genetic aberrations of<i>NLRC5</i>are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma Open
Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma. Twenty to twenty‐five percent of FL patients have progression of disease within 24 months. These patients may benefit from immunotherapy if intact antigen presentat…
View article: LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma Open
Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunot…
View article: Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration Open
PURPOSE Understanding the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) remains a priority. Solid tumors with low levels of intratumoral immune infi…
View article: COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study Open
In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or …
View article: The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma
The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma Open
Objective Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma (EBV ‐pos DLBCL) is a recently identified entity. Data regarding outcome to frontline immuno‐chemotherapy are conflicting. Although the prognostic impact of the tumour mic…
View article: An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy Open
A plethora of individual candidate biomarkers for predicting biochemical relapse in localized prostate cancer (PCa) have been proposed. Combined biomarkers may improve prognostication, and ensuring validation against more clinically releva…
View article: Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL Open
Key Points Expansion of PD-1+ CD3−CD56hiCD16-ve NK cells and PD-L1+ monocytes/macrophages is more prominent in cHL than DLBCL. PD-1 blockade reverses the immune evasion mediated by the interaction of PD-1+ NK cells and PD-L1+ monocytes/mac…
View article: ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R‐CHOP
ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R‐CHOP Open
Introduction: Immune checkpoint therapy has revolutionised the treatment of metastatic solid tumours. LAG3 is an immune checkpoint that is highly expressed on a variety of immune cells including a sub-population of ‘exhausted’ T cells. We …